Working… Menu

Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04013672
Recruitment Status : Active, not recruiting
First Posted : July 10, 2019
Last Update Posted : March 17, 2021
Information provided by (Responsible Party):
David Peereboom, MD, Case Comprehensive Cancer Center

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : May 2021
Estimated Study Completion Date : May 2021